Cargando…
Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
AmpC β-lactamase, altered porins, or both are usually responsible for cefoxitin resistance in Escherichia coli. We examined the relative importance of each. We studied 18 strains of clinical isolates with reduced cefoxitin susceptibility and 10 initially-susceptible strains passaged through cefoxiti...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033074/ https://www.ncbi.nlm.nih.gov/pubmed/14609460 http://dx.doi.org/10.3201/eid0910.030093 |
_version_ | 1782197533457514496 |
---|---|
author | Clarke, Brian Hiltz, Margot Musgrave, Heather Forward, Kevin R. |
author_facet | Clarke, Brian Hiltz, Margot Musgrave, Heather Forward, Kevin R. |
author_sort | Clarke, Brian |
collection | PubMed |
description | AmpC β-lactamase, altered porins, or both are usually responsible for cefoxitin resistance in Escherichia coli. We examined the relative importance of each. We studied 18 strains of clinical isolates with reduced cefoxitin susceptibility and 10 initially-susceptible strains passaged through cefoxitin-gradient plates. Of 18 wild-resistant strains, 9 had identical promoter mutations (including creation of a consensus 17-bp spacer) and related pulsed-field gel electrophoresis patterns; the other 9 strains were unrelated. Nine strains had attenuator mutations; two strains did not express OmpC or OmpF. After serial passage, 8 of 10 strains developed cefoxitin resistance, none developed promoter or attenuator mutations, 6 lost both the OmpC and OmpF porin proteins, and 1 showed decreased production of both. One strain had neither porin alteration or increased AmpC production. Porin mutants may occur more commonly and be less fit and less inclined to spread or cause disease than strains with increased β-lactamase expression. |
format | Text |
id | pubmed-3033074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-30330742011-02-09 Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada Clarke, Brian Hiltz, Margot Musgrave, Heather Forward, Kevin R. Emerg Infect Dis Research AmpC β-lactamase, altered porins, or both are usually responsible for cefoxitin resistance in Escherichia coli. We examined the relative importance of each. We studied 18 strains of clinical isolates with reduced cefoxitin susceptibility and 10 initially-susceptible strains passaged through cefoxitin-gradient plates. Of 18 wild-resistant strains, 9 had identical promoter mutations (including creation of a consensus 17-bp spacer) and related pulsed-field gel electrophoresis patterns; the other 9 strains were unrelated. Nine strains had attenuator mutations; two strains did not express OmpC or OmpF. After serial passage, 8 of 10 strains developed cefoxitin resistance, none developed promoter or attenuator mutations, 6 lost both the OmpC and OmpF porin proteins, and 1 showed decreased production of both. One strain had neither porin alteration or increased AmpC production. Porin mutants may occur more commonly and be less fit and less inclined to spread or cause disease than strains with increased β-lactamase expression. Centers for Disease Control and Prevention 2003-10 /pmc/articles/PMC3033074/ /pubmed/14609460 http://dx.doi.org/10.3201/eid0910.030093 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Clarke, Brian Hiltz, Margot Musgrave, Heather Forward, Kevin R. Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada |
title | Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada |
title_full | Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada |
title_fullStr | Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada |
title_full_unstemmed | Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada |
title_short | Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada |
title_sort | cephamycin resistance in clinical isolates and laboratory-derived strains of escherichia coli, nova scotia, canada |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033074/ https://www.ncbi.nlm.nih.gov/pubmed/14609460 http://dx.doi.org/10.3201/eid0910.030093 |
work_keys_str_mv | AT clarkebrian cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada AT hiltzmargot cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada AT musgraveheather cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada AT forwardkevinr cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada |